3B BlackBio DX
1,225.00
+49.70(+4.23%)
Market Cap₹1,051.35 Cr
PE Ratio17.34
Company Performance:
1D+4.23%
1M-2.16%
6M-11.90%
1Y-27.32%
5Y+262.27%
View Company Insightsright
More news about 3B BlackBio DX
06Feb 26
3B BlackBio Dx Limited Reports Strong Q3FY26 Financial Results with Consolidated Revenue of ₹5034.73 Lakhs
3B BlackBio Dx Limited reported strong Q3FY26 results with consolidated revenue of ₹5034.73 lakhs (up 98.30% YoY) and net profit of ₹2244.29 lakhs (up 66.30% YoY). Nine-month consolidated revenue reached ₹10648.40 lakhs with net profit of ₹5012.50 lakhs. The diagnostic kits segment drove growth with ₹4867.50 lakhs revenue, while CORIS acquisition contributed ₹2400.70 lakhs in sales and ₹700.10 lakhs in profit for the quarter.
 no imag found
30Jan 26
3B BlackBio Dx Limited Schedules Board Meeting for February 6, 2026 to Review Q3FY26 Financial Results
3B BlackBio Dx Limited has scheduled a board meeting for February 6, 2026, at 3:00 p.m. to consider and approve unaudited standalone and consolidated financial results for Q3FY26 and nine months ended December 31, 2025. The company has implemented trading window restrictions from January 1, 2026, until 48 hours after the results announcement, in compliance with SEBI insider trading regulations.
 no imag found
24Dec 25
3B BlackBio DX Promoter Sells 400 Shares in Open Market Transactions
3B BlackBio DX Limited disclosed that promoter Mahesh Kumar Upadhyay sold 400 equity shares in two tranches (150 on December 23 and 250 on December 24, 2025) through open market transactions. His shareholding reduced from 24,250 to 23,850 shares, maintaining 0.28% voting rights in the company's ₹8.58 crore equity capital structure.
 no imag found
13Nov 25
3B BlackBio DX Reports Strong Q2 Results with 37% Revenue Growth and Major Acquisition
3B BlackBio DX (formerly Kilpest India Limited) announced robust financial results for Q2 FY2026. Standalone revenue increased by 37.1% to 2,791.60 lakhs, while net profit grew 19.9% to 1,494.08 lakhs compared to the previous quarter. The company reported consolidated revenue of 3,890.21 lakhs, which includes the performance of its newly acquired subsidiary, Coris Holding SRL, Belgium. The acquisition was completed on August 29, 2025, incurring one-time expenses of 54.54 lakhs. 3B BlackBio DX operates in agrochemicals and molecular diagnostic kits segments, with a standalone basic EPS of Rs 17.44 for the quarter.
 no imag found
23Aug 25
3B BlackBio Dx Reports 18% Revenue Growth in Q1 FY26, Acquires Belgium-Based Coris Bioconcept
3B BlackBio Dx Limited, a leading Indian molecular diagnostics company, reported an 18% year-on-year increase in Q1 FY26 sales to ₹19.96 crores, with EBITDA growing 11% to ₹16.19 crores. The company acquired Coris Bioconcept, a Belgian rapid diagnostics firm, for up to £4.77 million to expand its European presence. 3B BlackBio Dx holds a 12-15% market share in India and projects 15-20% growth for FY26, outpacing industry expectations. The company aims to increase export contribution from 17-18% to 35-40% of total revenue within five years. EBITDA margins are around 60% but expected to trend towards 55% due to competition. Current capacity utilization is at 65% with no major capital expenditure needed for 2-3 years.
 no imag found
14Aug 25
3B BlackBio Dx Limited Reports Strong Q1 Results, Approves Key Board Appointments
3B BlackBio DX announced robust Q1 financial results. Standalone revenue reached Rs 2,035.71 lakhs with a profit after tax of Rs 1,246.04 lakhs. Consolidated revenue was Rs 2,223.46 lakhs with a profit after tax of Rs 1,264.45 lakhs. The company reappointed Mr. Dhirendra Dubey as Chairman and Managing Director, and appointed Mr. Vivek Saihgal as an Independent Director. Other expenses included one-time M&A advisory fees of Rs 84.06 lakhs for the acquisition of Coris Bioconcept SRL, Belgium.
 no imag found
28May 25
3B BLACKBIO DX Reports Q4 Results: Revenue Up, EBITDA Down, Final Dividend Recommended
3B BLACKBIO DX's Q4 financial results show a 4.68% YoY revenue increase to ₹230.20 crore, despite a 6.80% EBITDA decline to ₹94.60 crore. Net profit marginally improved by 1.54% to ₹92.40 crore. The company's board has recommended a final dividend of ₹4 per equity share, subject to shareholder approval.
 no imag found
3B BlackBio DX
1,225.00
+49.70
(+4.23%)
1 Year Returns:-27.32%
Industry Peers
Dr. Lal Path Labs
1,378.60
(+1.13%)
Metropolis Healthcare
456.00
(+4.97%)
Krsnaa Diagnostics
599.10
(+5.31%)
Suraksha Diagnostic
261.98
(+3.35%)
3B BlackBio DX
1,225.00
(+4.23%)
Sastasundar Ventures
267.55
(-0.07%)